STAT+: Doudna talks cost, access issues looming over first CRISPR therapy
“How do we make sure that a technology like CRISPR — you know, no offense intended — is not just going to make a few people rich, but it’s going…
News
STAT+: Hospitals say peak labor costs are behind them
Rising labor costs has been the main financial concern for hospitals over the past year, but those costs have peaked and are now a lot lower, according to hospital system… […]
News
STAT+: Gilead wins a key battle with the CDC over patents for its Truvada HIV pill
The judge noted the CDC did not alert Gilead to a patent on Truvada until 2016, one year after it had been issued. […]
News
STAT+: SVB, biotech’s bank of choice, just failed. It could have ripple effects
Silicon Valley Bank, which does business with roughly half of the nation’s tech and biotech companies, failed on Friday. Now biotech startups are left wondering: Who’s going to finance the… […]
